EIF2B4 and neoplasm: Complementing this, our in vivo models reveal that EIF2B4 fosters a “cold” tumor phenotype by impeding immune cell infiltration and upregulating PD-L1 to enforce adaptive immune resistance, thereby positioning EIF2B4 as a promising therapeutic target to enhance ICB sensitivity.